123 related articles for article (PubMed ID: 20204273)
1. Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours.
Srirajaskanthan R; Shah T; Watkins J; Marelli L; Khan K; Caplin ME
Oncol Rep; 2010 Apr; 23(4):909-15. PubMed ID: 20204273
[TBL] [Abstract][Full Text] [Related]
2. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue.
Ekberg T; Nestor M; Engström M; Nordgren H; Wester K; Carlsson J; Anniko M
Int J Oncol; 2005 May; 26(5):1177-85. PubMed ID: 15809707
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.
Hudelist G; Singer CF; Manavi M; Pischinger K; Kubista E; Czerwenka K
Breast Cancer Res Treat; 2003 Aug; 80(3):353-61. PubMed ID: 14503808
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.
Lee CH; Huntsman DG; Cheang MC; Parker RL; Brown L; Hoskins P; Miller D; Gilks CB
Int J Gynecol Pathol; 2005 Apr; 24(2):147-52. PubMed ID: 15782071
[TBL] [Abstract][Full Text] [Related]
6. Type 1 protein tyrosine kinases in benign and malignant breast lesions.
Suo Z; Emilsen E; Tveit KM; Nesland JM
Histopathology; 1998 Dec; 33(6):514-21. PubMed ID: 9870145
[TBL] [Abstract][Full Text] [Related]
7. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.
Xia W; Lau YK; Zhang HZ; Xiao FY; Johnston DA; Liu AR; Li L; Katz RL; Hung MC
Clin Cancer Res; 1999 Dec; 5(12):4164-74. PubMed ID: 10632356
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
[TBL] [Abstract][Full Text] [Related]
9. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
[TBL] [Abstract][Full Text] [Related]
10. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell JA; Rampaul RS; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
Br J Cancer; 2004 Oct; 91(8):1532-42. PubMed ID: 15480434
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.
Li W; Wang Y; Tan S; Rao Q; Zhu T; Huang G; Li Z; Liu G
Med Sci Monit; 2018 Oct; 24():7178-7185. PubMed ID: 30296252
[TBL] [Abstract][Full Text] [Related]
12. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) expression in childhood brain tumors.
Bodey B; Kaiser HE; Siegel SE
In Vivo; 2005; 19(5):931-41. PubMed ID: 16097449
[TBL] [Abstract][Full Text] [Related]
14. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
Tangjitgamol S; Ramirez PT; Sun CC; See HT; Jhingran A; Kavanagh JJ; Deavers MT
Int J Gynecol Cancer; 2005; 15(4):646-56. PubMed ID: 16014119
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.
Chow NH; Chan SH; Tzai TS; Ho CL; Liu HS
Clin Cancer Res; 2001 Jul; 7(7):1957-62. PubMed ID: 11448910
[TBL] [Abstract][Full Text] [Related]
16. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group).
Elie C; Geay JF; Morcos M; Le Tourneau A; Girre V; Broët P; Marmey B; Chauvenet L; Audouin J; Pujade-Lauraine E; Camilleri-Broët S;
Br J Cancer; 2004 Aug; 91(3):470-5. PubMed ID: 15226774
[TBL] [Abstract][Full Text] [Related]
17. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.
Kassouf W; Black PC; Tuziak T; Bondaruk J; Lee S; Brown GA; Adam L; Wei C; Baggerly K; Bar-Eli M; McConkey D; Czerniak B; Dinney CP
J Urol; 2008 Jan; 179(1):353-8. PubMed ID: 18006009
[TBL] [Abstract][Full Text] [Related]
18. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P
APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer.
García I; Vizoso F; Martín A; Sanz L; Abdel-Lah O; Raigoso P; García-Muñiz JL
Ann Surg Oncol; 2003 Apr; 10(3):234-41. PubMed ID: 12679307
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas.
Kountourakis P; Pavlakis K; Psyrri A; Rontogianni D; Xiros N; Patsouris E; Pectasides D; Economopoulos T
Cancer J; 2006; 12(3):229-36. PubMed ID: 16803682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
